US Patent

US11007208 — Methods for treating arenaviridae and coronaviridae virus infections

Method of Use · Assigned to Gilead Sciences Inc · Expires 2036-09-16 · 10y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods for treating Arenaviridae and Coronaviridae virus infections using specific nucleosides and their prodrugs.

USPTO Abstract

Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1â² position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.

Drugs covered by this patent

Veklury (remdesivir) · Gilead Sciences

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3831`	—	Veklury
`U-3829`	—	Veklury

Patent Metadata

Patent number: US11007208
Jurisdiction: US
Classification: Method of Use
Expires: 2036-09-16
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.